Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asunaprevir and daclatasvir plus peginterferon alfa-2a and ribavirin in prior null or partial responders with chronic hepatitis C genotype 1 or 4
2011-005422-21Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin in chronic hepatitis C (CHC), sponsored by Bristol Myers Squibb. Primary endpoint: SVR12 in genotype 1 subjects. Started Apr 2012; status: completed.
02
Drugs
asunaprevirdaclatasvirpeginterferon alfa-2aribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2011-005422-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005422-21.